1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Hepatic Encephalopathy Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Hepatic Encephalopathy Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Hepatic Encephalopathy Treatment by Country/Region, 2018, 2022 & 2029
2.2 Hepatic Encephalopathy Treatment Segment by Route
2.2.1 Oral
2.2.2 Injectable
2.3 Hepatic Encephalopathy Treatment Sales by Route
2.3.1 Global Hepatic Encephalopathy Treatment Sales Market Share by Route (2018-2023)
2.3.2 Global Hepatic Encephalopathy Treatment Revenue and Market Share by Route (2018-2023)
2.3.3 Global Hepatic Encephalopathy Treatment Sale Price by Route (2018-2023)
2.4 Hepatic Encephalopathy Treatment Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.5 Hepatic Encephalopathy Treatment Sales by Application
2.5.1 Global Hepatic Encephalopathy Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Hepatic Encephalopathy Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Hepatic Encephalopathy Treatment Sale Price by Application (2018-2023)
3 Global Hepatic Encephalopathy Treatment by Company
3.1 Global Hepatic Encephalopathy Treatment Breakdown Data by Company
3.1.1 Global Hepatic Encephalopathy Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Hepatic Encephalopathy Treatment Sales Market Share by Company (2018-2023)
3.2 Global Hepatic Encephalopathy Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Hepatic Encephalopathy Treatment Revenue by Company (2018-2023)
3.2.2 Global Hepatic Encephalopathy Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Hepatic Encephalopathy Treatment Sale Price by Company
3.4 Key Manufacturers Hepatic Encephalopathy Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Hepatic Encephalopathy Treatment Product Location Distribution
3.4.2 Players Hepatic Encephalopathy Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Hepatic Encephalopathy Treatment by Geographic Region
4.1 World Historic Hepatic Encephalopathy Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Hepatic Encephalopathy Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Hepatic Encephalopathy Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Hepatic Encephalopathy Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Hepatic Encephalopathy Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Hepatic Encephalopathy Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Hepatic Encephalopathy Treatment Sales Growth
4.4 APAC Hepatic Encephalopathy Treatment Sales Growth
4.5 Europe Hepatic Encephalopathy Treatment Sales Growth
4.6 Middle East & Africa Hepatic Encephalopathy Treatment Sales Growth
5 Americas
5.1 Americas Hepatic Encephalopathy Treatment Sales by Country
5.1.1 Americas Hepatic Encephalopathy Treatment Sales by Country (2018-2023)
5.1.2 Americas Hepatic Encephalopathy Treatment Revenue by Country (2018-2023)
5.2 Americas Hepatic Encephalopathy Treatment Sales by Route
5.3 Americas Hepatic Encephalopathy Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hepatic Encephalopathy Treatment Sales by Region
6.1.1 APAC Hepatic Encephalopathy Treatment Sales by Region (2018-2023)
6.1.2 APAC Hepatic Encephalopathy Treatment Revenue by Region (2018-2023)
6.2 APAC Hepatic Encephalopathy Treatment Sales by Route
6.3 APAC Hepatic Encephalopathy Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Hepatic Encephalopathy Treatment by Country
7.1.1 Europe Hepatic Encephalopathy Treatment Sales by Country (2018-2023)
7.1.2 Europe Hepatic Encephalopathy Treatment Revenue by Country (2018-2023)
7.2 Europe Hepatic Encephalopathy Treatment Sales by Route
7.3 Europe Hepatic Encephalopathy Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Hepatic Encephalopathy Treatment by Country
8.1.1 Middle East & Africa Hepatic Encephalopathy Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Hepatic Encephalopathy Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Hepatic Encephalopathy Treatment Sales by Route
8.3 Middle East & Africa Hepatic Encephalopathy Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Hepatic Encephalopathy Treatment
10.3 Manufacturing Process Analysis of Hepatic Encephalopathy Treatment
10.4 Industry Chain Structure of Hepatic Encephalopathy Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Hepatic Encephalopathy Treatment Distributors
11.3 Hepatic Encephalopathy Treatment Customer
12 World Forecast Review for Hepatic Encephalopathy Treatment by Geographic Region
12.1 Global Hepatic Encephalopathy Treatment Market Size Forecast by Region
12.1.1 Global Hepatic Encephalopathy Treatment Forecast by Region (2024-2029)
12.1.2 Global Hepatic Encephalopathy Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Hepatic Encephalopathy Treatment Forecast by Route
12.7 Global Hepatic Encephalopathy Treatment Forecast by Application
13 Key Players Analysis
13.1 Mallinckrodt Pharmaceuticals
13.1.1 Mallinckrodt Pharmaceuticals Company Information
13.1.2 Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.1.3 Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Mallinckrodt Pharmaceuticals Main Business Overview
13.1.5 Mallinckrodt Pharmaceuticals Latest Developments
13.2 Salix Pharmaceuticals
13.2.1 Salix Pharmaceuticals Company Information
13.2.2 Salix Pharmaceuticals Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.2.3 Salix Pharmaceuticals Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Salix Pharmaceuticals Main Business Overview
13.2.5 Salix Pharmaceuticals Latest Developments
13.3 GlaxoSmithKline plc.
13.3.1 GlaxoSmithKline plc. Company Information
13.3.2 GlaxoSmithKline plc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.3.3 GlaxoSmithKline plc. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GlaxoSmithKline plc. Main Business Overview
13.3.5 GlaxoSmithKline plc. Latest Developments
13.4 Pfizer Inc.
13.4.1 Pfizer Inc. Company Information
13.4.2 Pfizer Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.4.3 Pfizer Inc. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Pfizer Inc. Main Business Overview
13.4.5 Pfizer Inc. Latest Developments
13.5 ASKA Pharmaceutical Co., Ltd.
13.5.1 ASKA Pharmaceutical Co., Ltd. Company Information
13.5.2 ASKA Pharmaceutical Co., Ltd. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.5.3 ASKA Pharmaceutical Co., Ltd. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 ASKA Pharmaceutical Co., Ltd. Main Business Overview
13.5.5 ASKA Pharmaceutical Co., Ltd. Latest Developments
13.6 Bausch Health
13.6.1 Bausch Health Company Information
13.6.2 Bausch Health Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.6.3 Bausch Health Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bausch Health Main Business Overview
13.6.5 Bausch Health Latest Developments
13.7 Johnson & Johnson Services, Inc.
13.7.1 Johnson & Johnson Services, Inc. Company Information
13.7.2 Johnson & Johnson Services, Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.7.3 Johnson & Johnson Services, Inc. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Johnson & Johnson Services, Inc. Main Business Overview
13.7.5 Johnson & Johnson Services, Inc. Latest Developments
13.8 Janssen Global Services
13.8.1 Janssen Global Services Company Information
13.8.2 Janssen Global Services Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.8.3 Janssen Global Services Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Janssen Global Services Main Business Overview
13.8.5 Janssen Global Services Latest Developments
13.9 Takeda Pharmaceutical Company Limited
13.9.1 Takeda Pharmaceutical Company Limited Company Information
13.9.2 Takeda Pharmaceutical Company Limited Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.9.3 Takeda Pharmaceutical Company Limited Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Takeda Pharmaceutical Company Limited Main Business Overview
13.9.5 Takeda Pharmaceutical Company Limited Latest Developments
13.10 Merck & Co., Inc.
13.10.1 Merck & Co., Inc. Company Information
13.10.2 Merck & Co., Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.10.3 Merck & Co., Inc. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Merck & Co., Inc. Main Business Overview
13.10.5 Merck & Co., Inc. Latest Developments
14 Research Findings and Conclusion
| ※参考情報 肝性脳症は、肝不全や肝疾患によって引き起こされる脳の機能障害であり、主にアンモニアや他の有害物質が血液中に蓄積されることが原因です。この状態は、身体の代謝や神経系にさまざまな影響を及ぼし、軽度の意識障害から重度の昏睡状態まで、広範囲にわたる症状を引き起こすことがあります。 肝性脳症は、肝機能が低下することによって発生するため、肝疾患の進行度に応じて症状が変化します。症状には、注意障害、混乱、精神的な変化、運動障害、さらには意識障害や昏睡状態が含まれます。これらの症状は、特に肝硬変や急性肝不全の患者においてよく見られます。また、特定の要因、たとえば感染、脱水、電解質異常などが誘因となり、肝性脳症が急激に悪化することがあります。 治療の基本的な考え方は、肝臓が代謝するべき有害物質の蓄積を抑制し、かつ肝機能をサポートすることです。具体的には、食事療法、薬物療法、場合によっては肝移植が考慮されます。 食事療法としては、高たんぱく食の制限が推奨されることが一般的です。肝性脳症の患者は、食事からのたんぱく質が血中アンモニアレベルを上昇させるため、この要素を管理することが重要です。ただし、過度な制限は栄養不良を引き起こす可能性があるため、適切なバランスを考慮する必要があります。 薬物療法には、ラクトロースやリファキシミンなどが使用されます。ラクトロースは、腸内でアンモニアを減少させる働きがあります。これは、ラクトロースが腸内で発酵されることによって酸性環境を作り、アンモニアが吸収されるのを防ぐ仕組みです。一方、リファキシミンは腸内の有害な細菌を減少させ、これに伴ってアンモニアの産生を抑制することが期待されます。 肝移植は、肝性脳症が重度であり、他の治療法が無効な場合には、最終的な治療手段として検討されます。しかし、肝移植には適応基準があり、移植を受けるためには、患者の全体的な健康状態や肝不全の進行度などを評価する必要があります。 関連技術としては、血液透析や肝補助療法が挙げられます。血液透析は、体内の毒素を除去する手段として、肝性脳症の急性増悪時に有効とされることがあります。また、肝補助療法は、肝機能が低下している患者に対して、肝臓の機能を一時的に補助することを目的とした治療法です。これにより、一時的に肝機能をサポートし、症状の軽減を図ります。 肝性脳症の治療は、患者一人ひとりの状態に応じて個別化されるべきです。症状の重症度、基礎疾患、合併症の有無などを考慮し、最適な管理を行うことが肝要です。また、定期的なモニタリングと専門医による状態の評価も不可欠です。 現在、肝性脳症に対する研究が進行中であり、新しい治療法や診断基準の確立が期待されています。患者へのより良いケアを提供するために、専門的な知識と最新の情報を基にしたアプローチが求められています。 このように肝性脳症は、重篤な合併症を引き起こす可能性があるため、その予防と早期発見・治療が非常に重要です。肝疾患の管理や新たな治療法の開発が進む中で、肝性脳症の患者のQOL（生活の質）の向上が期待されています。また、医療従事者は、患者やその家族に対して十分な情報提供とサポートを行い、この疾患を理解し適切に対処できるような環境を整えることが求められます。肝性脳症は、肝疾患の重要な合併症であり、今後も引き続き注目されるテーマであると言えるでしょう。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
